StockNews.com assumed coverage on shares of Revance Therapeutics (NASDAQ:RVNC – Free Report) in a report issued on Monday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.
Other equities research analysts have also recently issued reports about the company. HC Wainwright reaffirmed a “neutral” rating and issued a $6.60 target price on shares of Revance Therapeutics in a report on Friday, November 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a research note on Friday, November 8th. Barclays lowered their target price on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research report on Monday, December 23rd. Finally, Mizuho reduced their price target on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a research report on Tuesday, December 10th. Nine investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $8.39.
View Our Latest Stock Report on RVNC
Revance Therapeutics Price Performance
Revance Therapeutics (NASDAQ:RVNC – Get Free Report) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The company had revenue of $59.88 million for the quarter, compared to the consensus estimate of $67.73 million. As a group, equities analysts expect that Revance Therapeutics will post -1.57 EPS for the current year.
Hedge Funds Weigh In On Revance Therapeutics
Several large investors have recently modified their holdings of the stock. Bank of New York Mellon Corp boosted its stake in Revance Therapeutics by 22.5% during the second quarter. Bank of New York Mellon Corp now owns 373,015 shares of the biopharmaceutical company’s stock worth $959,000 after buying an additional 68,451 shares during the period. Rhumbline Advisers lifted its holdings in shares of Revance Therapeutics by 11.6% in the 2nd quarter. Rhumbline Advisers now owns 136,347 shares of the biopharmaceutical company’s stock worth $350,000 after acquiring an additional 14,191 shares during the last quarter. Arizona State Retirement System boosted its stake in shares of Revance Therapeutics by 27.6% during the 2nd quarter. Arizona State Retirement System now owns 27,716 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 5,996 shares during the period. Los Angeles Capital Management LLC grew its holdings in Revance Therapeutics by 25.2% during the 2nd quarter. Los Angeles Capital Management LLC now owns 116,368 shares of the biopharmaceutical company’s stock valued at $299,000 after purchasing an additional 23,450 shares during the last quarter. Finally, Federated Hermes Inc. grew its holdings in Revance Therapeutics by 43.0% during the 2nd quarter. Federated Hermes Inc. now owns 2,237,505 shares of the biopharmaceutical company’s stock valued at $5,750,000 after purchasing an additional 672,803 shares during the last quarter. Institutional investors own 97.70% of the company’s stock.
About Revance Therapeutics
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.
See Also
- Five stocks we like better than Revance Therapeutics
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- 5 Top Rated Dividend Stocks to Consider
- How Do Stock Buybacks Affect Shareholders?
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.